Amylin as a potential link between type 2 diabetes and Alzheimer's disease
Martinez-Valbuena I (1,2,3), Valenti-Azcarate R (1,2,3), Amat-Villegas I (3,4), Riverol M (1,3), Marcilla I (2,3), de Andrea CE (5), Sánchez-Arias JA (3,6), Del Mar Carmona-Abellan M (1,2,3), Marti G (1,3), Erro E (3,7), Martínez-Vila E (1,3), Tuñon MT (3,4), Luquin MR (1,2,3).
(1) Neurology Department, Clínica Universidad de Navarra, Pamplona, Spain.
(2) Regenerative Therapy Laboratory, Neurosciences Division, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
(3) Navarra's Health Research Institute (IDISNA), Pamplona, Spain.
(4) Pathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
(5) Pathology Department, Clínica Universidad de Navarra, Pamplona, Spain.
(6) Small Molecule Discovery Platform, Molecular Therapeutics Program, CIMA, University of Navarra, Pamplona, Spain.
(7) Neurology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Alzheimer's disease (AD) is the leading cause of dementia and although its etiology remains unclear, it seems that type two diabetes mellitus (T2DM) and other pre-diabetic states of insulin resistance could contribute to the appearance of sporadic AD. As such, we have assessed whether tau and Aβ deposits might be present in pancreatic tissue of subjects with AD, and whether amylin, an amyloidogenic protein deposited in the pancreas of T2DM patients, might accumulate in the brain of AD patients.
We studied pancreatic and brain tissue from 48 individuals with no neuropathological alterations, and from 87 subjects diagnosed with AD. We examined Aβ and tau accumulation in the pancreas, as well as that of amylin in the brain. Moreover, we performed proximity ligation assays to ascertain whether tau and/or Aβ interact with amylin in either the pancreas or brain of these subjects.
Cytoplasmic tau and Aβ protein deposits were detected in pancreatic β-cells of subjects with AD, as well as in subjects with a normal neuropathological examination but with a history of T2DM and in a small cohort of control subjects without T2DM. Furthermore, we found amylin deposits in the brain of these subjects, providing histological evidence that amylin can interact with Aβ and tau in both the pancreas and hippocampus.
The presence of both tau and Aβ inclusions in pancreatic β cells, and of amylin deposits in the brain, provides new evidence of a potential overlap in the mechanisms underlying the pathogenesis of T2DM and AD.
CITATION Ann Neurol. 2019 Aug 3. doi: 10.1002/ana.25570